Download Baumann AKA Off label 09

Literaturliste AKA-Artikel
Psychopharmaka – Off Label Use 1/2
Psychopharmaka – Off Label Use 2/2
Pierre Baumann, Pierre Voirol
(1) Fuchs CR, Beutler M. Antidepressiva - nicht nur bei Depressionen. Journal suisse de
pharmacie 2006;3:76-81.
(2) Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. World Federation of Societies
of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of
anxiety, obsessive- compulsive and posttraumatic stress disorders. World J Biol
Psychiatry 2002 Oct;3(4):171-99.
(3) Breyer-Pfaff U, Gaertner HJ, Baumann P. Antidepressiva - Pharmakologie,
therapeutischer Einsatz und Klinik der Depressionen. 2 ed. Stuttgart - Germany:
Wissenschaftliche Verlagsgesellschaft mbH Stuttart; 2005.
(4) Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, et al.
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International
Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for
the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009
May;11(3):225-55.
(5) Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers
and antipsychotics in the maintenance phase of bipolar disorder: a systematic review
of randomized controlled trials. Bipolar Disord 2007 Jun;9(4):394-412.
(6) Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World
Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological
treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J
Biol Psychiatry 2009;10(2):85-116.
(7) Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ. The World Federation of
Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of
bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004
Jul;5(3):120-35.
(8) Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of
available data and clinical perspectives. Int J Neuropsychopharmacol 2008
Nov;11(7):999-1029.
(9) Baumann P. La prescription off label dans le cadre des troubles bipolaires soulève des
questions en pratique clinique. PSY and PSY 2009;(in presss).
(10) Compendium Suisse des médicaments 2009. Basle, Switzerland: Documed SA; 2009.
(11) Baldwin DS, Kosky N. Off-label prescribing in psychiatric practice. Adv Psychiatr Treat
2007 Nov 1;13(6):414-22.
(12) Wetterling T. Rechtsprechung zur Verabreichung von Medikamenten ausserhalb der
zugelassenen Indikationsgebiete. Fortschr Neurol Psychiatr 2004 May;72(5):255-9.
(13) Zullino DF, Cottier AC, Besson J. Topiramate in opiate withdrawal. Prog
Neuropsychopharmacol Biol Psychiatry 2002;26:1221-3.
(14) Sartorius N, Baghai TC, Baldwin DS, Barrett B, Brand U, Fleischhacker W, et al.
Antidepressant medications and other treatments of depressive disorders: a CINP
Task Force report based on a review of evidence. The International Journal of
Neuropsychopharmacology 2007;10(Supplement S1):S1-S207.
(15) Nickel MK, Nickel C, Muehlbacher M, Leiberich PK, Kaplan P, Lahmann C, et al.
Influence of topiramate on olanzapine-related adiposity in women - A random,
double-blind, placebo-controlled study. J Clin Psychopharmacol 2005 Jun;25(3):2117.
f
o
w
e
i
v
e
r
a
:
s
d
n
e
r
t
g
n
i
b
i
r
c
s
e
r
p
c
i
t
o
h
c
y
s
p
i
t
n
A
s
e
i
d
u
t
s
l
a
c
i
g
o
l
o
i
m
e
d
i
p
e
o
c
a
m
r
a
h
p
(16) Verdoux H, Tournier M, Bégaud B.
. Acta Psychiatr Scand 2009;in press.
(17) Zullino DF, Bilancioni R, Conus P, Schwartz B, Khazaal Y, Baumann P. Off-label
utilization of antipsychotics. South African Psychiatry Review 2006;9:38-43.
(18) Fountoulakis KN, Nimatoudis I, Iacovides A, Kaprinis G. Off-label indications for
atypical antipsychotics: a systematic review. Annals of General Hospital Psychiatry
2004;3:4.
(19) Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al.
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic
variations to the phenotype of drug response. Mol Psychiatry 2004 May;9(5):442-73.
(20) Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Kuss HJ, et al. The AGNPTDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.
Pharmacopsychiatry 2004;37:243-65.
(21) Bertilsson L, Dahl ML, Dalen P, Al Shurbaji A. Molecular genetics of CYP2D6: clinical
relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002 Feb;53:111-22.
(22) Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The
Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006
update. [78 refs]. J Clin Psychiatry 2007 Nov;68(11):1751-62.
(23) Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors Focus on newer generation compounds. Life Sci 2000 Nov 24;68(1):29-39.
(24) Boggs DL, Kelly DL, Feldman S, McMahon RP, Nelson MW, Yu Y, et al. Quetiapine at
high doses for the treatment of refractory schizophrenia. Schizophr Res 2008
Apr;101(1-3):347-8.
(25) Delacrétaz E. Medikamente und verlängertes QT-Intervall. Schweiz Med Forum
2007;7:817-9.
(26) Albrecht A, Morena PG, Baumann P, Eap CB. High dose of depot risperidone in a
nonresponder schizophrenic patient. J Clin Psychopharmacol 2004;24(6):673-4.
(27) Adli M, Baethge C, Heinz A, Langlitz N, Bauer M. Is dose escalation of antidepressants
a rational strategy after a medium-dose treatment has failed? A systematic review.
2
Eur Arch Psychiatry Clin Neurosci 2005 Dec;255(6):387-400.
(28) Le Bloc'h Y, Woggon B, Weissenrieder H, Brawand-Amey M, Spagnoli J, Eap CB, et al.
Routine therapeutic drug monitoring in patients treated with 10-360 mg/day
citalopram. Ther Drug Monit 2003;25:600-8.
(29) Neuvonen PJ, Pohjola-Sintonen S, Tacke U, Vuori E. Five fatal cases of serotonin
syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses.
Lancet 1993;342:1419.
(30) Voirol P, Hodel PF, Zullino D, Baumann P. Serotonin syndrome after small doses of
citalopram or sertraline. J Clin Psychopharmacol 2000;20:713-4.
(31) Mbaya P. Safety and efficacy of high dose of venlafaxine XL in treatment resistant
major depression. Hum Psychopharmacol Clin Exp 2002 Oct;17(7):335-9.
(32) Haller-Gloor F, Eap CB, Baumann P. High-dose venlafaxine treatment in a depressed
patient with a genetic CYP2D6 deficiency. Int J Psych Clin Pract 2004;8(3):191-5.
(33) Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of
obsessive-compulsive disorder. Int Clin Psychopharmacol 2008 Jan;23(1):49-53.
3